Tom,
Sorry for the late reply. Yes, quite exciting times. September is here and I am convinced we crossed through at least the 30% improvement in DFS. The one wild card is the exact number of enrolled patients in each group 20 months ago. I think my model is fairly close to the real numbers, but no way to know for sure. If these numbers are accurate and historical recurrence rates are holding for this patient population then we will be celebrating soon! I updated the model (same numbers, calcs, etc) to a more visual graph on my Twitter account.
IDMC PR was telling. No CardioTox issues and no deviations was big. This meeting was in June, so I'm assuming if called for futility it would have happen in this meeting of they had up to date trial numbers.
Mitt's presentation was amazing. The bolded ER/PR- NeuVax phase II patients vs. Control patients is striking. This pop has a much higher recurrence rate regardless of Her2+ status. I have the paper if you need it. 1/30 recurrences for patients with above median E-75 positive T's. Wow what an efficacy Biomarker. The slides on vaccine efficacy depending on disease state. Mitt's tone change for immunotherapy in BC. Hope we get a readout on the combo low Her2 trial soon. I could go on but this is a game changer and I'm proud my investment dollars help fund it!!
AI
